HLS Therapeutics
TSE:HLSHLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
SPI Energy
NASDAQ:SPISPI Energy Co., Ltd. provides photovoltaic and electric vehicle (EV) solutions for business, residential, government, and utility customers and investors in Australia, Japan, Italy, the United States, the United Kingdom, and Greece. The company offers engineering, procurement, and construction services to independent power developers and producers, and commercial and industrial companies. It also develops, owns, and operates solar projects that sell electricity to power companies and other electricity off-takers, including government-owned utility companies. In addition, the company sells self-assembled solar modules, forklifts, pre-development solar projects, component and charging stations, as well as offers shipping, delivery, engineering, and maintenance services. As of April, 2022, it owned and operated 17.51 megawatts of solar projects. The company is headquartered in Sacramento, California.